Figure 1:
CONSORT diagram. Adapted from Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): updated overall survival analysis.